Related references
Note: Only part of the references are listed.The dopamine D3 receptor, a quarter century later
Pierre Sokoloff et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2017)
ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease
Angelo Antonini et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson's disease, atypical Parkinsonian disorders and non-Parkinsonian populations
Eimer M. Maloney et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Valerie Voon et al.
LANCET NEUROLOGY (2017)
Impulse Control Disorders in Advanced Parkinson's Disease With Dyskinesia: The ALTHEA Study
Roberta Biundo et al.
MOVEMENT DISORDERS (2017)
Neurobiology and neuropharmacology of monoaminergic systems
Philippe De Deurwaerdere et al.
PROGRESS IN NEUROBIOLOGY (2017)
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
Rajesh Pahwa et al.
JAMA NEUROLOGY (2017)
Pharmacogenetics of Parkinson's Disease in Clinical Practice
Jean-Christophe Corvol et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2017)
Carbidopa/Levodopa ER Capsules (Rytary®, Numient™): A Review in Parkinson's Disease
Sarah L. Greig et al.
CNS DRUGS (2016)
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
Rajeev Kumar et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2016)
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Dhanya Vijayakumar et al.
DRUGS (2016)
Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease
Julia Kraemmer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
Joaquim J. Ferreira et al.
LANCET NEUROLOGY (2016)
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
Claudia Trenkwalder et al.
MOVEMENT DISORDERS (2016)
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
Francois Tison et al.
MOVEMENT DISORDERS (2016)
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2016)
Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease
Roberto Cilia et al.
PARKINSONISM & RELATED DISORDERS (2016)
Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients
Soumya Krishnamoorthy et al.
PARKINSONISM & RELATED DISORDERS (2016)
Nondopaminergic treatments for Parkinson's disease: current and future prospects
Maria Eliza Freitas et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2016)
Serotonin in Parkinson's disease
Marios Polotis et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia
Milica Cerovic et al.
BIOLOGICAL PSYCHIATRY (2015)
DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients
Shahidee Zainal Abidin et al.
BMC NEUROLOGY (2015)
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease
Caroline Moreau et al.
BRAIN (2015)
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study
Per Svenningsson et al.
BRAIN (2015)
A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
Tomoyoshi Kondo et al.
CLINICAL NEUROPHARMACOLOGY (2015)
Gene Expression Analyses Identify Narp Contribution in the Development of L-DOPA-Induced Dyskinesia
Fanny Charbonnier-Beaupel et al.
JOURNAL OF NEUROSCIENCE (2015)
Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial
Claudia Trenkwalder et al.
LANCET NEUROLOGY (2015)
Gastrointestinal dysfunction in Parkinson's disease
Alfonso Fasano et al.
LANCET NEUROLOGY (2015)
Dopaminergic regulation of olfactory type G-protein subunit expression in the striatum
I. Ruiz-DeDiego et al.
MOVEMENT DISORDERS (2015)
New Treatments for Levodopa-Induced Motor Complications
Olivier Rascol et al.
MOVEMENT DISORDERS (2015)
Zooming in on the Small: The Plasticity of Striatal Dendritic Spines in L-DOPA-Induced Dyskinesia
Tim Fieblinger et al.
MOVEMENT DISORDERS (2015)
Parkinson's Disease Treatment May Cause Impulse-Control Disorder Via Dopamine D3 Receptors
Philip Seeman
SYNAPSE (2015)
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease Two Randomized Clinical Trials and Lessons Learned
Robert A. Hauser et al.
JAMA NEUROLOGY (2015)
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease
Manuela Pilleri et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder
M. L. Fantini et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
The Medical Treatment of Parkinson Disease from James Parkinson to George Cotzias
Stanley Fahn
MOVEMENT DISORDERS (2015)
Improving L-dopa Therapy: The Development of Enzyme Inhibitors
Oscar S. Gershanik
MOVEMENT DISORDERS (2015)
Levodopa Therapy for Parkinson's Disease: Pharmacokinetics and Pharmacodynamics
Peter A. LeWitt
MOVEMENT DISORDERS (2015)
Presynaptic Effects of Levodopa and Their Possible Role in Dyskinesia
Eugene V. Mosharov et al.
MOVEMENT DISORDERS (2015)
Levodopa: Effect on Cell Death and the Natural History of Parkinson's Disease
C. Warren Olanow
MOVEMENT DISORDERS (2015)
The Addiction-Related Gene ANKK1 in Parkinsonian Patients with Impulse Control Disorder
Janet Hoenicka et al.
NEUROTOXICITY RESEARCH (2015)
Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5
Tim Fieblinger et al.
JOURNAL OF NEUROSCIENCE (2014)
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Stephane Palfi et al.
LANCET (2014)
for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
C. W. Olen et al.
LANCET NEUROLOGY (2014)
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Delayed Gastric Emptying in Parkinson's Disease
Sarah Marrinan et al.
MOVEMENT DISORDERS (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and L-DOPA induced dyskinesia in mouse models
Sherri L. Thiele et al.
NEUROBIOLOGY OF DISEASE (2014)
Immediate-early gene expression in structures outside the basal ganglia is associated to L-DOPA-induced dysldnesia
Matthieu F. Bastide et al.
NEUROBIOLOGY OF DISEASE (2014)
Withdrawing amantadine in dyskinetic patients with Parkinson disease The AMANDYSK trial
Fabienne Ory-Magne et al.
NEUROLOGY (2014)
Naltrexone for impulse control disorders in Parkinson disease A placebo-controlled study
Kimberly Papay et al.
NEUROLOGY (2014)
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
David Devos et al.
PARKINSONISM & RELATED DISORDERS (2014)
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia
Myriam Heiman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications
M. Angela Cenci
FRONTIERS IN NEUROLOGY (2014)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
C. Warren Olanow et al.
LANCET NEUROLOGY (2014)
Levodopa Gains Psychostimulant-Like Properties after Nigral Dopaminergic Loss
Michel Engeln et al.
ANNALS OF NEUROLOGY (2013)
Complexity of dopamine metabolism
Johannes Meiser et al.
CELL COMMUNICATION AND SIGNALING (2013)
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
J. J. Ferreira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism
Stephan Klebe et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2013)
AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2013)
Screening for impulse control symptoms in patients with de novo Parkinson disease A case-control study
Daniel Weintraub et al.
NEUROLOGY (2013)
Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat
Yildiz Zengin-Toktas et al.
NEUROPHARMACOLOGY (2013)
Neurostimulation for Parkinson's Disease with Early Motor Complications
W. M. M. Schuepbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease
Philippe Huot et al.
PHARMACOLOGICAL REVIEWS (2013)
Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls
J. L. Riddle et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
Gαolf Mutation Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated Kinase-Dependent Signaling in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia
Cristina Alcacer et al.
JOURNAL OF NEUROSCIENCE (2012)
Regulation of prefrontal excitatory neurotransmission by dopamine in the nucleus accumbens core
Wengang Wang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Neuropathology of Sporadic Parkinson's Disease: Evaluation and Changes of Concepts
Kurt A. Jellinger
MOVEMENT DISORDERS (2012)
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease
Lissa S. Brod et al.
MOVEMENT DISORDERS (2012)
Caffeine for treatment of Parkinson disease A randomized controlled trial
Ronald B. Postuma et al.
NEUROLOGY (2012)
Dopaminergic Modulation of Synaptic Transmission in Cortex and Striatum
Nicolas X. Tritsch et al.
NEURON (2012)
Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease
Jee-Young Lee et al.
PARKINSONISM & RELATED DISORDERS (2012)
Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders
Annamaria Vallelunga et al.
PARKINSONISM & RELATED DISORDERS (2012)
Addictive behaviors and Parkinson's disease
T. Witjas et al.
REVUE NEUROLOGIQUE (2012)
The COMT Val158Met Polymorphism Affects the Response to Entacapone in Parkinson's Disease: A Randomized Crossover Clinical Trial
Jean-Christophe Corvol et al.
ANNALS OF NEUROLOGY (2011)
Modulation of Striatal Projection Systems by Dopamine
Charles R. Gerfen et al.
ANNUAL REVIEW OF NEUROSCIENCE, VOL 34 (2011)
Cyclic Adenosine Monophosphate-Independent Tyrosine Phosphorylation of NR2B Mediates Cocaine-Induced Extracellular Signal-Regulated Kinase Activation
Vincent Pascoli et al.
BIOLOGICAL PSYCHIATRY (2011)
Impulse control disorders in Parkinson's disease: recent advances
Valerie Voon et al.
CURRENT OPINION IN NEUROLOGY (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
The Impact of Non-Motor Symptoms on Health-Related Quality of Life of Patients with Parkinson's Disease
Pablo Martinez-Martin et al.
MOVEMENT DISORDERS (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
Klaus Seppi et al.
MOVEMENT DISORDERS (2011)
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
Daniela Berg et al.
MOVEMENT DISORDERS (2011)
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata
Claudia Rangel-Barajas et al.
NEUROBIOLOGY OF DISEASE (2011)
Does levodopa accelerate the pathologic process in Parkinson disease brain?
L. Parkkinen et al.
NEUROLOGY (2011)
The long-duration response to levodopa: Phenomenology, potential mechanisms and clinical implications
Elise Anderson et al.
PARKINSONISM & RELATED DISORDERS (2011)
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Jean-Martin Beaulieu et al.
PHARMACOLOGICAL REVIEWS (2011)
Sustained-release Madopar HBS® compared with standard Madopar® in the long-term treatment of de novo parkinsonian patients
E. Dupont et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Genetic and Environmental Influences on Disordered Gambling in Men and Women
Wendy S. Slutske et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Impulse Control Disorders in Parkinson Disease A Cross-Sectional Study of 3090 Patients
Daniel Weintraub et al.
ARCHIVES OF NEUROLOGY (2010)
Pharmacokinetics of levodopa
Manuela Contin et al.
JOURNAL OF NEUROLOGY (2010)
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Paolo Barone et al.
LANCET NEUROLOGY (2010)
Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2010)
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry
Alexxai V. Kravitz et al.
NATURE (2010)
Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors
Michael J. Higley et al.
NATURE NEUROSCIENCE (2010)
Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat
Manon Lebel et al.
NEUROBIOLOGY OF DISEASE (2010)
Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease Report of the Quality Standards Subcommittee of the American Academy of Neurology
T. A. Zesiewicz et al.
NEUROLOGY (2010)
GABAB Receptors Modulate NMDA Receptor Calcium Signals in Dendritic Spines
Jason R. Chalifoux et al.
NEURON (2010)
Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors
Valerie Voon et al.
NEURON (2010)
Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Kenneth A. Follett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Controlled-protein dietary regimens for Parkinson's disease
Emanuele Cereda et al.
NUTRITIONAL NEUROSCIENCE (2010)
Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia
Emanuela Santini et al.
PLOS ONE (2010)
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
Helen S. Bateup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia
Stefania Fasano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia
M. Angela Cenci et al.
RECENT ADVANCES IN PARKINSONS DISEASE: BASIC RESEARCH (2010)
Cell-Based Therapies for Parkinson's Disease: Past, Present, and Future
Kathleen M. Fitzpatrick et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA-Induced Dyskinesia and Histone Activation
Sanja Darmopil et al.
BIOLOGICAL PSYCHIATRY (2009)
Rotigotine transdermal delivery for the treatment of Parkinson's disease
Olivier Rascol et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice
Emanuela Santini et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L-DOPA-Induced Dyskinesia
Amandine Berthet et al.
JOURNAL OF NEUROSCIENCE (2009)
Differential Dopaminergic Modulation of Neostriatal Synaptic Connections of Striatopallidal Axon Collaterals
Fatuel Tecuapetla et al.
JOURNAL OF NEUROSCIENCE (2009)
Activation of Glycogen Synthase Kinase-3β Is Required for Hyperdopamine and D2 Receptor-Mediated Inhibition of Synaptic NMDA Receptor Function in the Rat Prefrontal Cortex
Yan-Chun Li et al.
JOURNAL OF NEUROSCIENCE (2009)
Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
Daniella Rylander et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
K. Ray Chaudhuri et al.
LANCET NEUROLOGY (2009)
Association of DRD3 and GRIN2B with Impulse Control and Related Behaviors in Parkinson's Disease
Jee-Young Lee et al.
MOVEMENT DISORDERS (2009)
Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
Susan H. Fox et al.
MOVEMENT DISORDERS (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The neurobiology and genetics of impulse control disorders: Relationships to drug addictions
Judson A. Brewer et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease: A Prospective Multicenter Study
Irena Rektorova et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study
Fabrizio Stocchi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Irregular gastrointestinal drug absorption in Parkinson's disease
Dag Nyholm et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum
Huaxia Tong et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by L-DOPA treatment
M. Rafuddin Ahmed et al.
JOURNAL OF NEUROCHEMISTRY (2008)
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease
Stephen J. Gold et al.
JOURNAL OF NEUROSCIENCE (2007)
Heart valve regurgitation, pergolide use, and Parkinson disease
Jean-Christophe Corvol et al.
ARCHIVES OF NEUROLOGY (2007)
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors
Jenny E. Westin et al.
BIOLOGICAL PSYCHIATRY (2007)
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients
Pablo Martinez-Martin et al.
MOVEMENT DISORDERS (2007)
Medication-related impulse control and repetitive behaviors in Parkinson Disease
Valerie Voon et al.
ARCHIVES OF NEUROLOGY (2007)
Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia
Barbara Valastro et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia
Emanuela Santini et al.
JOURNAL OF NEUROSCIENCE (2007)
Differences in ultrastructural localization of dopaminergic D1 receptors between dorsal striatum and nucleus accumbens in the rat
Brigitte Dumartin et al.
NEUROSCIENCE LETTERS (2007)
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia
M. Angela Cenci
TRENDS IN NEUROSCIENCES (2007)
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Paolo Calabresi et al.
TRENDS IN NEUROSCIENCES (2007)
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease
Flora Mela et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Anatol C. Kreitzer et al.
NATURE (2007)
Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia
M. Angela Cenci et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking
PJ Hallett et al.
JOURNAL OF NEUROSCIENCE (2006)
Protein kinase A regulates calcium permeability of NMDA receptors
VA Skeberdis et al.
NATURE NEUROSCIENCE (2006)
Pergolide versus levodopa monotherapy in early Parkinson's disease patients:: The PELMOPET study
WH Oertel et al.
MOVEMENT DISORDERS (2006)
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990
JA Van Gerpen et al.
ARCHIVES OF NEUROLOGY (2006)
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models
M Day et al.
NATURE NEUROSCIENCE (2006)
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice
N Pavon et al.
BIOLOGICAL PSYCHIATRY (2006)
Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D-2 receptors
K Hakansson et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Pharmacokinetic optimisation in the treatment of Parkinson's disease - An update
D Nyholm
CLINICAL PHARMACOKINETICS (2006)
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic -: Pharmacodynarnic pattern in patients with Parkinson's disease
M Contin et al.
MOVEMENT DISORDERS (2005)
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy
L Mazzella et al.
PARKINSONISM & RELATED DISORDERS (2005)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Doparnine D1-receptors modulate lateral inhibition between principal cells of the nucleus accumbens
S Taverna et al.
JOURNAL OF NEUROPHYSIOLOGY (2005)
The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling
KL Dunn et al.
BIOCHEMISTRY AND CELL BIOLOGY (2005)
The dopamine D-3 receptor and drug dependence: Effects on reward or beyond?
B Le Foll et al.
NEUROPHARMACOLOGY (2005)
Increased D-1 dopamine receptor signaling in levodopa-induced dyskinesia
I Aubert et al.
ANNALS OF NEUROLOGY (2005)
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
G Van Camp et al.
LANCET (2004)
Clozapine improves dyskinesias in Parkinson disease - A double-blind, placebo-controlled study
F Durif et al.
NEUROLOGY (2004)
Persistent increase in olfactory type G-protein α subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease
JC Corvol et al.
JOURNAL OF NEUROSCIENCE (2004)
Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms
PJ Blanchet et al.
PARKINSONISM & RELATED DISORDERS (2004)
Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
JC Tong et al.
ANNALS OF NEUROLOGY (2004)
The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1
G Krapivinsky et al.
NEURON (2003)
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
CW Olanow et al.
ANNALS OF NEUROLOGY (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines
VD Nair et al.
BIOCHEMICAL JOURNAL (2003)
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
B Picconi et al.
NATURE NEUROSCIENCE (2003)
Discrete coding of reward probability and uncertainty by dopamine neurons
CD Fiorillo et al.
SCIENCE (2003)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
Slowing Parkinson's disease progression - Recent dopamine agonist trials
JE Ahlskog
NEUROLOGY (2003)
Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress
C Mytilineou et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype
A Rivera et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor
FJS Lee et al.
CELL (2002)
A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission
SA Kotecha et al.
NEURON (2002)
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
RA Hauser et al.
MOVEMENT DISORDERS (2002)
D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase
CR Gerfen et al.
JOURNAL OF NEUROSCIENCE (2002)
Evolution of the response to levodopa during the first 4 years of therapy
JG Nutt et al.
ANNALS OF NEUROLOGY (2002)
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease
MS Lee et al.
NEUROLOGY (2002)
The additive effect of neurotransmitter genes in pathological gambling
DE Comings et al.
CLINICAL GENETICS (2001)
Differential dependence of the D1 and D5 dopamine receptors on the G protein γ7 subunit for activation of adenylylcyclase
Q Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
CR Freed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease
MJ Hurley et al.
MOLECULAR BRAIN RESEARCH (2001)
Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study
A Schrag et al.
BRAIN (2000)
Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
R Holloway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Molecular effects of dopamine on striatal-projection pathways
CR Gerfen
TRENDS IN NEUROSCIENCES (2000)
Golfα mediates dopamine D1 receptor signaling
XX Zhuang et al.
JOURNAL OF NEUROSCIENCE (2000)
Serotonin release from mesencephalic raphe neurons grafted to the 5,7-dihydroxytryptamine-lesioned rat hippocampus:: Effects of behavioral activation and stress
MA Cenci et al.
EXPERIMENTAL NEUROLOGY (2000)
Positron emission tomography provides molecular imaging of biological processes
ME Phelps
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Quality of life as a predictor for change in disability in MS
MW Nortvedt et al.
NEUROLOGY (2000)
Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo
GL Snyder et al.
JOURNAL OF NEUROSCIENCE (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
